

Lewy bodies, a form of PD. It was a sign I was the first to describe in print. I didn't think to give it a name, and merely called it, "rhinorrhea," since that's the technical term for a runny nose. I thought it mildly important as another sign of sympathetic denervation in PD, a finding which might function as an additional "pre-motor" sign of the disease, that is, a feature, which, along with several others, increases the risk

that an older person will develop PD in the near future. I had not thought of it as a sign that might help confirm the diagnosis of PD or related disease. I was ecstatic to be cited, but I am hopeful that the "runny nose sign," proud as I am at having identified it for the first time, will not be replaced by an eponymic. This is not a sign to be proud of. I also continue to worry whenever my nose runs for a few days. ❖

#### Author

Joseph H. Friedman, MD, is Editor-in-chief of the *Rhode Island Medical Journal*, Professor and the Chief of the Division of Movement Disorders, Department of Neurology at the Alpert Medical School of Brown University, chief of Butler Hospital's Movement Disorders Program and first recipient of the Stanley Aronson Chair in Neurodegenerative Disorders.

#### Disclosures on website

### LETTER TO THE EDITOR

#### AMA Urges EpiPen Manufacturer to Rein in Exorbitant Costs

On Aug. 24th, Andrew W. Gurman, MD, president of the American Medical Association, issued the following statement regarding the cost of EpiPens, which have risen to more than \$600 for a twin-pack:

"With Americans across the country sending their children back to school this month, many parents and schools are encountering sticker shock over the cost of EpiPens. Although the product is unchanged since 2009, the cost has skyrocketed by more than 400 percent during that period. The AMA has long urged the pharmaceutical industry to exercise reasonable restraint in drug pricing, and, with lives on the line, we urge the manufacturer to do all it can to rein in these exorbitant costs. With many parents required to buy two or more sets of EpiPens just to keep their children safe, the high cost of these devices may either keep them out of reach of people in need or force some families to choose between EpiPens and other essentials. The AMA will continue to promote market-based strategies to achieve access to and affordability of health care goods and services." ❖